Literature DB >> 22337177

Contribution of mu and delta opioid receptors to the pharmacological profile of kappa opioid receptor subtypes.

D I Brissett1, J L Whistler, R M van Rijn.   

Abstract

Molecular cloning has identified three opioid receptors: mu (MOR), delta (DOR) and kappa (KOR). Yet, cloning of these receptor types has offered little clarification to the diverse pharmacological profiles seen within the growing number of novel opioid ligands, which has led to the proposal of multiple subtypes. In the present study, utilizing in vitro and in vivo methods including the use of opioid receptor knockout mice, we find that certain antinociceptive effects of the KOR-1 and KOR-2 subtype-selective ligands (+)-(5α,7α,8β)-N-Methyl-N-[7-(1-pyrrolidinyl)-1-oxaspiro[4.5]dec-8-yl]-benzene-acetamide (U69, 593) and 4-[(3,4-Dichlorophenyl)acetyl]-3-(1-pyrrolidinylmethyl)-1-piperazine-carboxylic acid methyl ester fumarate (GR89, 696), respectively, are potentiated by antagonism of MOR and DOR receptors. We believe that our findings can be best explained by the existence of KOR-DOR and KOR-MOR heteromers. We only find evidence for the existence of these heteromers in neurons mediating mechanical nociception, but not thermal nociception. These findings have important clinical ramifications as they reveal new drug targets that may provide avenues for more effective pain therapies.
© 2011 European Federation of International Association for the Study of Pain Chapters.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22337177      PMCID: PMC4086711          DOI: 10.1002/j.1532-2149.2011.00022.x

Source DB:  PubMed          Journal:  Eur J Pain        ISSN: 1090-3801            Impact factor:   3.931


  56 in total

1.  Heterodimerization of mu and delta opioid receptors: A role in opiate synergy.

Authors:  I Gomes; B A Jordan; A Gupta; N Trapaidze; V Nagy; L A Devi
Journal:  J Neurosci       Date:  2000-11-15       Impact factor: 6.167

Review 2.  Clinical pharmacology of opioids for pain.

Authors:  Charles E Inturrisi
Journal:  Clin J Pain       Date:  2002 Jul-Aug       Impact factor: 3.442

3.  Mice deficient for delta- and mu-opioid receptors exhibit opposing alterations of emotional responses.

Authors:  D Filliol; S Ghozland; J Chluba; M Martin; H W Matthes; F Simonin; K Befort; C Gavériaux-Ruff; A Dierich; M LeMeur; O Valverde; R Maldonado; B L Kieffer
Journal:  Nat Genet       Date:  2000-06       Impact factor: 38.330

4.  A bivalent ligand (KDN-21) reveals spinal delta and kappa opioid receptors are organized as heterodimers that give rise to delta(1) and kappa(2) phenotypes. Selective targeting of delta-kappa heterodimers.

Authors:  Rashmi G Bhushan; Shiv K Sharma; Zhihua Xie; David J Daniels; Philip S Portoghese
Journal:  J Med Chem       Date:  2004-06-03       Impact factor: 7.446

5.  A role for heterodimerization of mu and delta opiate receptors in enhancing morphine analgesia.

Authors:  Ivone Gomes; Achla Gupta; Julija Filipovska; Hazel H Szeto; John E Pintar; Lakshmi A Devi
Journal:  Proc Natl Acad Sci U S A       Date:  2004-03-24       Impact factor: 11.205

6.  Antagonism by naloxone of narcotic-induced respiratory depression and analgesia.

Authors:  K L McGilliard; A E Takemori
Journal:  J Pharmacol Exp Ther       Date:  1978-11       Impact factor: 4.030

7.  Identity of the putative delta1-opioid receptor as a delta-kappa heteromer in the mouse spinal cord.

Authors:  Philip S Portoghese; Mary M Lunzer
Journal:  Eur J Pharmacol       Date:  2003-04-25       Impact factor: 4.432

8.  GR89,696: a potent kappa-opioid agonist with subtype selectivity in rhesus monkeys.

Authors:  E R Butelman; M C Ko; J R Traynor; J A Vivian; M J Kreek; J H Woods
Journal:  J Pharmacol Exp Ther       Date:  2001-09       Impact factor: 4.030

9.  Demonstration of the heterogeneity of the kappa-opioid receptors in guinea-pig cerebellum using selective and nonselective drugs.

Authors:  M Tiberi; J Magnan
Journal:  Eur J Pharmacol       Date:  1990-06-12       Impact factor: 4.432

10.  Intrathecal morphine in mice: a new technique.

Authors:  J L Hylden; G L Wilcox
Journal:  Eur J Pharmacol       Date:  1980-10-17       Impact factor: 4.432

View more
  2 in total

Review 1.  Comprehensive overview of biased pharmacology at the opioid receptors: biased ligands and bias factors.

Authors:  Jolien De Neve; Thomas M A Barlow; Dirk Tourwé; Frédéric Bihel; Frédéric Simonin; Steven Ballet
Journal:  RSC Med Chem       Date:  2021-04-21

Review 2.  A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists.

Authors:  Kendall L Mores; Benjamin R Cummins; Robert J Cassell; Richard M van Rijn
Journal:  Front Pharmacol       Date:  2019-04-17       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.